Skip to content

Effects of a Test Food Containing an Extract of Unripe Mandarins for Reducing Allergic Reaction of Eyes or Nose.

Effects of a Test Food Containing an Extract of Unripe Mandarins for Reducing Allergic Reaction of Eyes or Nose. - Effects of a Test Food Containing an Extract of Unripe Mandarins for Reducing Allergic Reaction of Eyes or Nose.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000039243
Enrollment
68
Registered
2020-01-23
Start date
2020-01-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N/A(healthy adults)

Interventions

Oral ingestion of the test food (2 capsules once a day for 12 weeks). Oral ingestion of the placebo food (2 capsules once a day for 12 weeks).

Sponsors

TES Holdings Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: [1]Japanese males and females aged 20-64 years. [2]Individuals who are healthy and are not suffered from a chronic malady. [3]Individuals with allergic reaction of eyes and nose in early spring. [4]Individuals whose written informed consent has been obtained. [5]Individuals who can visit an inspection facility and be inspected in designated days. [6]Individuals judged appropriate for the study by the principal.

Exclusion criteria

Exclusion criteria: [1]Individuals using medical products. [2][2]Individuals who use an antiallergic drug or steroid drug or will use during the test period. [3]Individuals who have history of intranasal laser therapy to reduce allergic symptoms. [4]Individuals who are a patient of or have a history of bronchial disease. [5]Individuals who are patient or have a history of mental disease, psychiatric disease, high blood pressure, diabetes, and hyperlipidemia. [6]Individuals who used a drug to treat a disease in the past 1 month (except temporal usage for pollenosis). [7]Individuals who are sensitive to other foods and medical products. [8]Individuals who contract or have a history of serious hepatopathy, kidney damage, heart disease and blood disease. [9]Individuals who are a patient or have a history of or endocrine disease. [10]Individuals whose BMI is over 30 kg/m2. [11]Individuals who donated blood over 200mL in the past 1 month or over 400mL in the past 3 months. [12]Individuals who had a habit to ingest health-promoting foods, foods for specified health uses, health foods, or supplements containing similar composition with a test food in the past 1 month or will ingest those foods during the test period. [13]Individuals who had a habit to ingest health-promoting foods, foods for specified health uses, health foods, or supplements in the past 1 months or will ingest those foods during the test period to reduce allergic symptoms. [14]Individuals who excessively take alcohol (expressed in an amount of alcohol: over 60 mg/day). [15]Individuals with possible changes of life style, such as conducting a long-term travel, during the test period. [16]Individuals who are or are possibly, or are lactating. [17]Individuals who have a habit to use drug claiming to improve skin condition in the past 3 months. [18]Individuals who are or whose family is engaged in healthy or functional foods. [19]Individuals judged inappropriate for the study by the principal.

Design outcomes

Primary

MeasureTime frame
[1]Indexes for allergic rhinitis (Japan Rhinitis Quality of Life Questionnaire No. 1(1), grading the severity of allergic rhinitis(2), grading of local findings(2), eyes and nose condition based on subject's diary(3), effect measurement(4)) (1):Week 0, 2, 4, 6, 8, 10, 12. (2):Week 0, 6, 12. (3)From the first day of ingestion of a test material to the last day of the test. (4)Week 12.

Secondary

MeasureTime frame
*Secondary outcomes [1]Specific measurementf of nasal discharge and blood (nasal discharge eosinophils(1), eosinophil(1), nonspecific IgE(1), specific IgE(2)). (1):Week 0, 6, 12. (2):Week 0, 12. *Safety evaluation [1]Hematologic test(1). [2]Blood biochemical test(1). [3]Urine analysis(1). [4]Blood pressure, pulsation(1). [5]Weight, body fat percentage, BMI(1). [6]Doctor's questions(1). (1):Week 0, 6, 12. *Other indexes [1]Questionnaire for allergic rhinitis(1). [2]Subject's diary(2). (1):Week 0. (2)From the first day of ingestion of a test material to the last day of the test.

Countries

Japan

Contacts

Public ContactRyoma Shimizu

TES Holdings Co., Ltd. Administrative Department of Clinical Trials

r.shimizu@tes-h.co.jp+81-3-6801-8480

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026